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Abstract
Background: Coronary bypass graft failure as a result of acute thrombosis and intimal hyperplasia has been the major
challenge in surgical procedures involving small-diameter vascular prosthesis. Coating synthetic grafts with patients’ own
endothelial cells has been suggested to improve the patency rate and overall success of bypass surgeries.
Methodology/Principal Findings: We isolated endothelial progenitor cells (EPCs) from leftover pieces of human saphenous
vein/mammary artery. We demonstrate that EPCs can be expanded to generate millions of cells under low-density culture
conditions. Exposure to high-density conditions induces differentiation to endothelial cell phenotype. EPC–derived
endothelial cells show expression of CD144
high, CD31, and vWF. We then assessed the ability of differentiated endothelial
cells to adhere and grow on small diameter expanded polytetrafluoroethylene (ePTFE) tubings. Since ePTFE tubings are
highly hydrophobic, we optimized protocols to introduce hydrophilic groups on luminal surface of ePTFE tubings. We
demonstrate here a stepwise protocol that involves introduction of hydrophilic moieties and coating with defined ECM
components that support adhesion of endothelial cells, but not of blood platelets.
Conclusion/Significance: Our data confirms that endothelial progenitors obtained from adult human blood vessels can be
expanded in vitro under xenoprotein-free conditions, for potential use in endothelialization of small diameter ePTFE grafts.
These endothelialized grafts may represent a promising treatment strategy for improving the clinical outcome of small-
caliber vascular grafts in cardiac bypass surgeries.
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Introduction
Coronary artery disease is the most prevalent heart disease that
occurs because of stenosis/narrowing and blockage of coronary
arteries, restricting the blood flow to myocardium (heart muscles).
Although several treatment strategies for coronary artery disease are
in use, it is known to be the cause of over 7 million deaths/year
worldwide [1]. These treatments include medical management
(Statins, antihypertensive, smoking cessation as well as blood glucose
control in diabetic conditions), percutaneous coronary interventions
(PCI: balloon angioplasty, coronary stents, drug eluting stents and
other devices to treat chronic total occlusions) and coronary artery
bypass graft (CABG) surgery. CABG involves surgical removal of
blood vessels (usually saphenous vein) from patient’s body and
graftingthistothecoronaryarteriessoastobypasstheatherosclerotic
narrowing in order to improve blood supply to the myocardium.
Both PCI and CABG are more effective than medical
management at relieving coronary artery disease [2–4] but CABG
is considered superior to PCI in multi-vessel coronary disease
treatment with lower rates of death, myocardial infarction and
repeat revascularization [5]. Autologous grafts are normally used in
such surgeries but in case of 30–40% patients, these vessels are
unsuitable for surgery. With this limited availability of autologous
blood vessels, synthetic grafts have gained popularity and have been
in regular use as the only alternative. The materials of choice are
ePTFE (expanded poly tetra fluoro ethylene), Dacron (PET- poly
ethylene tetrapthalate), and polycarbonate polyurethane (PU).
However, though these vessels are biocompatible, they lack
endothelial cell lining, which results in poor patency of such
synthetic vascular grafts. Endothelial cells provide a physical
interface between blood and surrounding tissues and also maintain
a haemostatic-thrombotic balance that regulates inflammation and
angiogenesis. It is proposed that endothelialization of artificial
prosthesis using autologous vascular endothelial cells would help in
improving the patency rates of these grafts [6–8]. Furukawa et al
have also shown that endothelial cell monolayers demonstrate better
blood compatibility than either ePTFE or silicone sheets alone [9].
However synthetic vascular grafts do not spontaneously endothelia-
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endothelial cells adhesion, cell spreading and growth. Surface
modification of ePTFE tubes so as to make them suitable for
adhesion and growth of autologous endothelial cells for better
endothelialization and patency of ePTFE grafts has been examined
in various in vitro and in vivo models [10–13]. Though such
synthetic vascular grafts are non-immunogenic they demonstrate
increased platelet aggregation/thrombosis and stenosis as compared
to autologous vessels, especially when their diameter is small [14].
Platelet aggregation has been demonstrated to be an important
determinant of graft failure [15,16] in such small caliber vascular
prosthesis. The luminal surface of ePTFE is highly hydrophobic,
thereby inhibiting endothelialization of synthetic grafts in situ and
also allowing for increased thrombus formation. There is therefore a
need to change the surface properties of synthetic small caliber
vascular grafts to avoid platelet aggregation along with better
endothelialization. The other limitation is to achieve large numbers
of transplantable autologous human endothelial cells. Endothelial
cells are derived from their progenitors, known as hemangioblasts
during embryonic development. These precursors are characterized
byexpression of CD133 [17].Thesecells are highlyproliferativeand
play an important role in regeneration of damaged and ischemic
tissues by angiogenesis and repair of damaged blood vessels [18].
Several studies carried out till now describe isolation of human EPCs
from peripheral blood [19], umbilical cord blood [20], bone marrow
[21], adipose tissues [22], skeletal muscles [23], and organs such as
heart [24], and Spleen [25]. Although EPCs have been known to be
present in arterial wall as CD133
+ cells [26], and in vascular
endothelial cell population in vitro as flk1
+ cells [27], isolation,
expansionanddifferentiationofCD133expressingEPCsfromblood
vessel has not been demonstrated as yet. We show here that CD133
+
EPCs can be isolated from human arterial/venous samples.
Secondly, unlike previous reports wherein CD133-expressing cells
were seen to differentiate in vitro and lose CD133-expression [28],
our data suggests that the expression of CD133 depends on cell-cell
interactions during the phase of expansion. Such cell-cell and cell-
matrix interactions are indeed known to play an important role in
differentiation of endothelial cells [29,30]. However,wedemonstrate
here for the first time that CD133-expressing cells obtained in vitro
can be maintained and expanded in vitro for at least 20 passages (20
cell doublings or 2
‘20=a million fold). Exposure of these EPCs to
high density culture conditions induces expression of CD144, a
marker of mature endothelial cells, which also express CD31 and
vWF. We also describe a stepwise protocol wherein ePTFE tubings
can be efficiently coated with such in vitro differentiated endothelial
cells. A defined extracellular matrix combination, which we refer to
as ‘‘OptiMat’’, was shown to allow better adhesion and growth of
endothelial cells. Surface modification of ePTFE tubings as well as
OptiMat coating of these surfaces was essential in achieving better
endothelialization of small diameter (4 mm) ePTFE grafts. Suchpre-
treated, OptiMat-coated small diameter ePTFE grafts offer minimal
platelet aggregation in a simulated arterial blood flow system with
better retention of seeded endothelial cells during in vitro flow stress.
The step-wise surface modification strategy and endothelialization
protocol discussed herein may help to increase the overall patency
and efficacy of small diameter vascular grafts in cardiac bypass
surgeries.
Results
Isolation, expansion, and characterization of endothelial
progenitor cells (EPCs)
Endothelial progenitor cells were isolated from small pieces (1–
3 cm) of human saphenous vein and/or mammary artery. Isolated
endothelial progenitor cells (EPCs)were expandedinvitro under low
cell density culture conditions (Figure 1A: 10
3 cells/cm
2). Such cells
show high expression of CD133 (CD133
high; red color histogram in
Figure 1C) and low expression of CD144 (CD144
low; red color
histogram in Figure 1D). For induction of differentiation to mature
endothelial cells, EPCs were plated at a high cell density
(8610
4 cells/cm
2) on tissue culture treated flasks. By 8 days of in
vitroculture, suchEPCsachievea matureendothelial cellphenotype
(Figure 1B) and transition from a CD133
high CD144
low to CD133
low
CD144
high cells (Figure 1C and 1D). The low density culture
protocol helps in generating larger number of CD133
+ endothelial
population from initially fewer CD133
+ endothelial progenitor cells;
EPCs (Figure S1). We observe that EPCs maintained under low
density culture conditions retain CD133 expression until they are
exposed to high density culture conditions (Figure S2). To confirm if
EPCs grown in culture were progenitor cells, clonogenicity of
CD133
+ endothelial progenitors was tested. Here we assessed the
ability of passage 15 (32000-fold expanded) EPCs to form colonies in
0.8%methylcellulosemedia(FigureS3).Weobservethatlow density
culture condition helps to retain their progenitor nature during in
vitro culture. After such in vitro expansion, EPCs could be efficiently
differentiated to mature endothelial cells by mere exposure to high
density culture conditions. Such in vitro differentiated endothelial
cells show a typical cobblestone morphology (Figure 1F) and exhibit
immunopositivity to endothelial markers CD31 (Figure 1G), CD144
(Figure 1H), vWF (Figure 1I), UEA1 (Figure 1J) and eNOS
(Figure 1K). They also express Vimentin (Figure 1L) and Caveolin
1( F i g u r e1 M )b u td on o ts h o wi m m u n o p o s i t i v i t yt oC D 1 4 ,a-SMA
and pan-cytokeratin (not shown). These cells could be expanded for
at least 20 passages (2
‘20 or at least a million-fold expansion) and
differentiated into endothelial cells without any significant change in
their morphology (Figure S4). In vitro culture protocol that we
demonstrate herein, allows for generation of endothelial cells
sufficient to cover at least 200 cm
2 area within two months from
isolation (Figure 1E).
Surface modification and a defined mixture of ECM
coating improve hydrophilicity of ePTFE grafts
We observed that the luminal surface of ePTFE tubing is highly
hydrophobic (Figure 2A; untreated ePTFE). We exposed the
hydrophobic surfaces of ePTFE tubing to acidified glycerol (7.48 M
H2SO4 in 20% glycerol) and 10% citric acid. Following this, ePTFE
tubingswerecoatedwithadefinedmixtureofextracellularmatrices
(henceforth referred to as ‘‘OptiMat’’; see methods for details) and
changes in hydrophobicity were assessed using water contact angle
(Figure 2A). We observed that ePTFE tubings that were exposed to
acidified glycerol and citrate prior to OptiMat-coating demonstrat-
ed reduction in surface hydrophobicity as evidenced by water
contact angle, which reduced from 125u to 105u (Figure 2A).
OptiMat-coating of these acid-treated surfaces rendered them
hydrophilic as observed by further reduction of water contact angle
to 70u (Figure 2A). Coating OptiMat on ePTFE prior to acid
treatment had no significant effect on hydrophilicity of the materials
(Figure S5). Hence the acid- treatment of ePTFE prior to OptiMat
coating is necessary to achieve hydrophilic surfaces. To assess
endothelial cell attachment on such surfaces, we used small
diameter (2–4 mm i.d) polystyrene capillaries. These tubings were
chosen as they demonstrate similar hydrophobicity (water contact
angle of 120u; data not shown) and have good optical properties.
Assessing endothelial cell adhesion on these tubes allowed us to
compare endothelialization during different steps of the seeding
protocol. We observed better attachment of endothelial cells on to
the acid-treated and OptiMat-coated capillaries (Figure 2C) as
compared to the untreated capillaries (Figure 2B).
Endothelialization of ePTFE
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Differentiated EPCs express several adhesion molecules that
have affinities to extra cellular matrix (ECM) components. In
order to understand specific ECM components that help in
adhesion of endothelial cells, we assessed adhesion of endothelial
cells on Fibronectin-, Collagen I-, and Collagen IV-coated ePTFE
surfaces (Figure 3A–3C). A combination of these 3 ECM
components (refered to as ‘‘OptiMat’’) was also tested
Figure 1. In vitro expansion, differentiation, and characterization of endothelial progenitor cells. DIC images of endothelial progenitor
cells (EPCs) during in vitro expansion (A) and differentiation (B). EPCs grow as highly proliferative and flattened cells during expansion (A) and
differentiate into mature endothelial cells with cobble stone morphology as seen in panel B. FACS analysis of these cells during expansion (red color
histogram) and after differentiation to mature endothelial cells (blue color histogram) is shown in (C,D). The black histograms in (C,D) represent the
isotypecontrols.(E)demonstrates theequivalentsurfaceareathat couldbeendothelializedbyEPCsobtainedduringinvitroexpansion.Characterization
of in vitro expanded and differentiated endothelial cells (F) shows that these cells are immunopositive for endothelial cell specific markers CD31, CD144,
vWF,UEA1, and eNOS (G-K). Besides these endothelial markers they also produce Vimentin and caveolin1 (L and M) Bar=10 mm.
doi:10.1371/journal.pone.0007718.g001
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better adhesion than that of the individual ECM components
(Figure 3A–3D).
Modifying the surface properties and coating ePTFE with
‘‘OptiMat’’ reduces platelet-adhesion
We placeduntreated and OptiMat-coatedePTFE tubings on to a
heart-lung machine for 3 days and Heparinized blood was flown
over it at a flow-rate of 3 liters/min. At the end of the study
(Figure 4A), ePTFE tubings were fixed and assessed for platelet
aggregation by scanning electron microscopy (Figure 4B) and
confocal microscopy (Figure 4D). Platelets and leucocytes are
known to be the key responders in small diameter ePTFE grafts
[31–33]. Assessing the deposition of platelets is known to be
important inevaluationofsyntheticgrafts. The surfacearea covered
by blood platelets over the luminal surface of untreated and treated
ePTFE tubings was assessed as detailed in methods (Figure 4C).
About 10-12-fold less platelet aggregation was observed on
OptiMat-coated ePTFE tubings as compared to untreated ePTFE
(Figure 4C and 4D). We observe fewer number of cells (b-actin
+)o n
treated and OptiMat-coated ePTFE tubings (Figure 4D). Treated
ePTFE tubings were also observed with less amount of fibronectin
(Figure 4D) adhered to them after blood flow assay, which indicates
decrease in thrombogenic nature [34–36].
Optimat coating helps in adhesion and growth of
endothelial cells on small diameter ePTFE tubings and
their retention during flow stress
Since pretreated and OptiMat coated ePTFE rafts demonstrat-
ed better adhesion of endothelial cells, we used 4 mm (i.d) ePTFE
tubings to assess endothelialization. Passage 15 EPCs were
differentiated and endothelial cells obtained at day 10 were
seeded on to ePTFE tubings using roller culture assembly as
described in the methods section. Untreated ePTFE surfaces show
limited adhesion of endothelial cells (Figure 5; Uncoated). In
Figure 2. Optimat coated ePTFE tubings show better hydrophilicity. Water contact angle measurements of untreated ePTFE tubings and
after each stage of treatment are shown in (A). Acid-treatment and OptiMat-coating (74 ng/cm
2) reduced the contact angle to as low as 70u
indicating conversion of hydrophobic surface (water contact angle 125u) to a hydrophilic surface (water contact angle 70u). For easy visualization of
cells, we used transparent polystyrene capillaries with similar hydrophobic properties to that of ePTFE tubings. We observed that endothelial cells
show minimal attachment to untreated surfaces (B) but better adhesion and growth over acid-treated and OptiMat-coated surfaces (C). White dotted
boxes in capillary images on left side in (B,C) are enlarged to visualize cell growth (shown on right side) in each capillary.
doi:10.1371/journal.pone.0007718.g002
Figure 3. Adhesion of endothelial cells on different ECM
components. Effect of matrices on endothelial cells adhesion over
ePTFE surface; Endothelial cells adhesion on individual matrices
(Fibronectin, Collagen I, and Collagen IV) coated ePTFE (A–C) and their
respective additive effects on OptiMat (a mixture of these three
matrices) coated ePTFE rafts (D). OptiMat coating over ePTFE shows
significant support to endothelial cell adhesion. Data represents
mean6SEM of at least 3 different biological replicates. * indicates
significance compared to 668 ng/cm
2 of OptiMat.
doi:10.1371/journal.pone.0007718.g003
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PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7718Figure 4. OptiMat coating to ePTFE grafts inhibit blood cells (platelets) adhesion. ePTFE coated with OptiMat allow minimal platelets
adhesion in blood flow condition in vitro. (A) Diagrammatic representation of blood flow through small diameter ePTFE tubings. After unidirectional
blood flow scanning electron microscopy (SEM) (B) and immunostaining (D) were done to see blood platelets adhesion. OptiMat coated ePTFE tubes
were observed with less number of blood cells (shown by arrow heads) adhered to them compared to untreated one (B). OptiMat coated tubes have
less CD41 (platelets marker) +ve cells than untreated tubes (D). Percent area covered by CD41 +ve cells was calculated from randomly selected areas
each of about 5000 mm
2 of grafts (C). (D) also shows less fibronectin deposition (either from blood plasma or produced from platelets) and b-actin
producing platelets on OptiMat coated tubes (D).
doi:10.1371/journal.pone.0007718.g004
Endothelialization of ePTFE
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cells on the treated and OptiMat-coated ePTFE tubings (Figure 5;
OptiMat coated). We observe that around 90% of the seeded
endothelial cells attached to the acid-treated and OptiMat-coated
tubings while majority (,70%) of the seeded endothelial cells
failed to attach on to the untreated ePTFE tubings. Endothelial
cell monolayers were seen to adhere better on treated and
OptiMat-coated ePTFE tubings. They could be maintained in
culture for at least 4 weeks. To assess the ability of such
endothelialized ePTFE tubings to retain seeded endothelial cells
under flow stress conditions, we placed these tubings in a chamber
that allowed unidirectional flow of media during in vitro culture
(Figure S6). Under such flow-stress conditions, we observed 55-
fold more retention of endothelial cells on OptiMat-coated ePTFE
tubings as compared to the untreated ePTFE tubings (Figure 5B
and 5C).
Discussion
Cardiac bypass surgery remains to be the present therapy for
‘coronary artery occlusions’ [37]. However, patency rates in such
procedures have been proposed to be dependant on several factors
including the type of graft, site of anastomosis and distal run-off
[38–40]. The development of an autologous hybrid vascular
prosthesis (synthetic vascular grafts seeded with patient’s own
endothelial cells) would certainly improve the outcome of cardiac
bypass surgeries. Synthetic grafts such as ePTFE, dacron and
polyurathane are durable and nonimmunogenic materials of
choice. Several reports demonstrated till now have confirmed that
coating of synthetic grafts with endothelial cells influences the
thrombosis and hyperplasia on engraftment [41–47]. However,
adhesion and growth of endothelial cells over these biomaterial
surfaces is the most crucial step, which limits the use of small
Figure 5. Endothelial cells grow as uniform monolayer on OptiMat coated ePTFE tubes and show better retention in flow stress in
vitro. Endothelial cells adhere and grow over the luminal surface of small diameter ePTFE tubings after acid treatments and OptiMat-coating. Cells
grown on acid-treated and OptiMat-coated ePTFE tubings in rolling culture (see text). They retain endothelial characteristics and show
immunopositivity to CD31 (A). Commercially available (Uncoated) tubes however show only a few patches of endothelial cells (A). Bar=10 mm.
Following exposure to unidirectional flow stress (see text) we measured the number of cells (by haemocytometer counting of cells after
trypsinization) retained on the ePTFE tubings (B). Some of these tubes were taken for microscopic studies (C). Acid-treated and OptiMat-coated ePTFE
tubings demonstrated better retention of endothelial cells than control (untreated) ePTFE tubings (B,C).
doi:10.1371/journal.pone.0007718.g005
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synthetic grafts with different proteins, peptides or metals
[10,11,13,48] has been reported. However, endothelialization of
small diameter prosthesis has remained a major problem that
limits the use of these synthetic vascular grafts in cardiac bypass
surgeries.
The aims of this present study were to optimize a protocol for
xenoprotein-free expansion of human endothelial progenitor cells
(EPCs) in vitro, differentiate these to mature endothelial cells and
then improve their growth efficacy on to commercially available
small diameter vascular grafts. We show here that EPCs can be
isolated and expanded in vitro under xeno-protein-free conditions.
Cells retain CD133 expression during expansion when maintained
under low density culture condition. It is indeed intriguing that
mere exposure to high density culture conditions induces
differentiation to endothelial cells. It appears that cell-cell and
cell-matrix interactions, as reported earlier [29,30] are indeed
critical regulators of endothelial differentiation. The ability to
achieve expansion for ,20 passages (million fold) using human AB
serum supplemented medium also suggests that it may be possible
to expand EPCs using patients’ own serum. We also demonstrate
that the hydrophobic properties of ePTFE can be modified to
render them hydrophilic following acid-treatment and coating
with a defined combination of ECM components (collagen-I, -IV
and fibronectin). This combination was seen to be more potent in
achieving better adhesion than individual components alone. We
observe that treatment of the ePTFE surface with acidified buffer
facilitates binding of OptiMat components to these synthetic
grafts. Coating of the ePTFE surface decreases the blood platelets
adhesion as compared to untreated ePTFE grafts (Figure 6). We
also observe fibronectin accumulation over these grafts. Fibronec-
tin assists in thrombus formation [34–36]. Interestingly treated and
OptiMat-coated ePTFE grafts show significant decline in
fibronectin deposition. Although studies by Keuren et al [49,50]
suggest that heparin in the blood can prevent thrombus formation
we do see significant differences in fibronectin deposition on
uncoated ePTFE as compared to treated and OptiMat coated
ePTFE tubings (Figure 4D). Further analysis using FTIR
spectroscopy is being carried out to assess the change in specific
functional group(s) in ePTFE. Though several individual ECM
components have been tried out to achieve better endothelial cells
adhesion on ePTFE surfaces [51–54] we demonstrate that a
combination of defined ECM components provides better cellular
adhesion and growth. Since collagen-I, -IV and fibronectin are
major components of natural extracellular matrix deposited by
these cells, we evaluated the combined effects of these ECM
components in this study.
Theinvitroflowstressstudyofendothelialcellsgrownonluminal
surface of commercially available ePTFE and OptiMat-coated
ePTFE tubes demonstrates the role of surface modification and
OptiMat-coating in retaining endothelial cells following flow stress.
Our study reports a simple method to modify the surface properties
of ePTFE grafts for achieving better endothelialization. These
studies demonstrate that human endothelial progenitor cells can be
isolated from adult blood vessels and expanded in vitro without
losingtheirprogenitornature.Thesecanthen besuccessfullyseeded
on to small diameter ePTFE tubings that have been treated and
coatedwith defined ECMcomponents.SuchOptiMat-coatedgrafts
would have tremendous potential for use in peripheral vascular
surgery or coronary surgery in patients with varicose veins, diffuse
Figure 6. Schematic representation of methodology. Commercially available ePTFE tubings (A) are highly hydrophobic as estimated by water
contact angle (WCA) of 125u. Following exposure to acidified glycerol and citrate buffer (B), the decrease in WCA allows for adhesion of few
endothelial cells, as well as platelets. However, coating these pre-treated ePTFE tubings with a defined composition of ECM components (OptiMat)
enhance selective adhesion and growth of endothelial cells without any detectable platelet aggregation.
doi:10.1371/journal.pone.0007718.g006
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conventional conduits for bypass surgeries. Our findings may help
in increasing the overall patency of small diameter vascular grafts
for potential use in coronary bypass surgeries.
Methods
Isolation and expansion of vascular endothelial
progenitor cells
Saphenous vein or mammary/thoracic artery was obtained from
left over pieces (1–3 cm long) that are generally discarded
(incinerated) as ‘‘biological waste’’ after cardiac bypass surgery.
Collection of such material was approved by the ethical committee
of the National Center for Cell Science, Pune and signed written
consent was obtained from adult patients (50 to 70 years old) who
underwent cardiac bypass surgery. All patient data was maintained
anonymous and referred to by a sample number. Endothelial
progenitor cells (EPCs) were isolated from these vascular tissues
following standard collagenase digestion procedure. Briefly, vascular
samples were collected in M199 medium supplemented with
antibiotics (penicillin 25 units/ml, streptomycin 25 mg/ml Gibco-
BRL, Burlington, ON and Ciprofloxacin 30 mg/ml). They were
immediately delivered to the laboratory within 2 to 6 hours and
washed thoroughly with sterile phosphate buffered saline (PBS) to
remove excess blood cells. EPCs were then detached from luminal
wall using 1 mg/ml collagenase (Sigma,St. Louis, MO) as static
incubation at 37uC for 15 to 20 min after clipping both ends of the
blood vessel. Small diameter mammaryarteries weredilated prior to
collagenase exposure. Cells were flushed out using sterile PBS and
collectedin15 mlFalcontubes.Theywerewashed twice with10 ml
PBS and seeded in 10% human AB sera and antibiotics (penicillin
5 unit/ml and streptomycin 5 mg/ml and 6 mg/ml Ciprofloxacin;
GIBCO-BRL, Burlington, ON) containing EGMM (Endothelial
Growth Medium Mix) made by mixing 50% M199 (GIBCO-BRL,
Burlington, ON) media in EBM-2 media (Lonza, Walkersville, Md).
Cells were then plated in 24-well tissue culture treated plates and
incubated in a humidified 5% CO2 incubator at 37uC. EPCs
obtained after isolation generally adhere to culture plates within 6 to
8 hours of isolation. Such cells grow as adherent populations of
highly proliferative CD133
+ EPCs in vitro. Non-adherent cells are
removed after overnight culture and adherent populations are
expanded under low density conditions (seeding density 1000 cells/
cm
2 and allowed to grow upto 60–70% confluency). Culture media
was changed every third day. For induction of differentiation, EPCs
were plated on tissue culture treated plates at a high density
(8610
4 cells/cm
2) for 8 days. Although CD144- or CD31-
producing cells were seen as early as 3 days in vitro (not shown), a
homogeneous monolayer of CD144 and CD-31 expressing cells was
seen by 8 to 10 days of exposure to high density culture conditions
(Figure 1F–1H). These cells were given a 1:2 split ratio while
passaging these as differentiated endothelial cells.
Flow cytometry staining and analysis
Endothelial cells were harvested at these two stages and were
washed with Ca
++Mg
++-containing PBS. After blocking with 4%
normal donkey serum for 20 min at 4uC primary antibody mouse
anti-CD144 (Chemicon, Temecula, CA) at 1:50 dilution was
added. Cells were incubated at 4uC for 45 min and then washed 3
times with 5 ml PBS. Secondary antibody, Alexa Fluor 488 goat
anti-mouse (Molecular Probes, Carlsbad, CA) was added at 1:100
dilution and incubated at 4uC for 45 min. The CD133 staining
was done by one step staining with PE tagged mouse anti-human
CD133 antibody (Milteney Biotec, Germany) at 1:50 dilution and
incubation at 4uC for 45 min. Cells were washed 3 times with 5 ml
PBS and cell pellets were re-suspended in 300 ml PBS. At least
10,000 events were acquired for each sample on a FACS Canto II
system (BD, Franklin Lakes, NJ) and analysis was carried out using
FACS Diva software
Immunostaining and confocal microscopy
Freshly isolated endothelial cells or those obtained after successive
passaging/expansion were characterized for expression of endothe-
lialproteins.Mouseanti-CD31antibody(Chemicon,Temecula,CA)
and mouse anti-CD 144(Chemicon, Temecula, CA) antibodies were
used at 1:100 dilutions. Rabbit anti-vWF (von Willibrand Factor;
Chemicon, Temecula, CA) and UEA1 (Ulex europeous agglutinin;
Sigma, St. Louis, MO), Rabbit anti-eNOS and mouse anti-vimentin
antibody (Chemicon, Temecula, CA) were also used at 1:100
dilution. Alexa-Fluor 488, Alexa-Fluor 546 and Alexa-Fluor 633
F(ab’)2 secondary antibodies (Molecular Probes, Carlsbad, CA) were
used at 1:200 dilution. Hoechst 33342 or propidium iodide was used
to visualize nuclei. Cells were fixed in 4% fresh paraformaldehyde,
permeabilized with chilled 50% methanol (wherever necessary),
blocked with 4% normal donkey serum and then incubated with
antisera. Primary antibodies were incubated overnight at 4uC,
washed with PBS and then incubated with the secondary antibodies
at 37uC for 1 hour. Slides were washed extensively in PBS and
mounted in Vectashield mounting medium (Vector Laboratories,
Burlingame, CA).Confocal images wereobtained using a Zeiss LSM
510 laser scanning microscope. Magnification, laser power and
detector gains were set below saturation and were identical across
samples. Results presented are representative fields confirmed from
at least 3 different biological samples.
Formulation of OptiMat
OptiMat was made by mixing equal volumes of 666 ng/ml
Fibronectin, 337 ng/ml Collagen I and 1 mg/ml Collagen IV. The
total protein concentration of OptiMat was determined to be
667.63 ng/ml (222 ng Fibronectin, 112.3 ng Collagen I, and
333.33 ng Collagen IV,). Thus, the additive effect of each of the
ECM components was tested in OptiMat.
Surface modification and water contact angle
measurement of ePTFE
ePTFE was presoaked in methanol and washed with sterile
water. Then they were exposed to acidified glycerol (7.48 M
H2SO4 in 20% glycerol) in boiling water bath for 4 hrs with
intermittent shaking and washed with sterile double distilled water.
Exposure to 10% citric acid solution (Wt/V in sterile water) at
37uC for 3 hrs was carried out prior to washing and preparing
them for OptiMat-coating. OptiMat 74 ng/cm
2 (Figure S7) was
added inside the tube and ends of the tube were sealed with
parafilm. Tubes were placed on a rotor (1 RPM) inside 37uC
incubator for overnight. The ePTFE tubes that were processed for
surface modifications were flattened and square pieces of
5m m 65 mm were obtained. Water drop contact angles were
measured with ‘‘Digidrop Contact Angle meter’’ (GBX, Surface
science technology, France) after each surface modification step.
Water contact angle helps to understand the hydrophilicity of the
ePTFE membrane. Data are represented as mean contact angle of
at least 6 ePTFE rafts from each experimental condition.
Adhesion assay
Since the surface properties of ePTFE are much different than
tissue culture plates, we carried out adhesion assays on 1 cm
2
ePTFE rafts. Surface properties of such ePTFE rafts were modified
with acidified glycerol and 10% citrate as mentioned above. Then
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‘‘OptiMat’’. For all adhesion assays two different concentrations of
each matrix (Fibronectin; 74 ng/cm
2 and 222 ng/cm
2, Collagen I;
37.4 ng/cm
2 and 112 ng/cm
2, Collagen IV; 111.11 ng/cm
2 and
333.33 ng/cm
2 and Optimat which is mixture of these matrices
with combined final concentration of 222.5 ng/cm
2 and 667.6 ng/
cm
2) were coated by incubating at 37uC for overnight. After
coating, ePTFE rafts were washed twice with plain medium and
1.5610
4 endothelial cells were seeded on each of the ePTFE rafts.
Rafts were incubated for 20 min at 37uC. At the end of this
incubation, all rafts were thoroughly washed with PBS to remove
any non-adherent cells, while adherent cells were trypsinized
and counted using a hemocytometer. Data are represented as
mean6SEM from 4 individual experiments.
Covering the luminal surface of the vessels with
endothelial cells
The inner area of OptiMat coated tube was calculated and
seeded with 6610
4 endothelial cells per cm
2 area in EBM-2 media
containing penicillin-streptomycin and Ciprofloxacin antibiotics.
They were incubated in rolling culture vessels at 1 RPM in 37uC
incubator for a week with replacing fresh media everyday and
assessing cell adhesionby counting the number of cellsinsuspension
after day 1 of the seeding. Counting cells in suspension helped us to
guess adhesion of cellsoverluminal surface of ePTFEtubes (herewe
couldn’t see the adherent cells as ePTFE tubings are opaque).
Percent adhesion was calculated [% adhesion = {(Number of cells
seeded – number of cells in suspension)/Number of cells seeded}
6100]. Trypan blue staining of the cells from these media was
carried out to assess the viability of these cells.
In vitro flow stress test
Unidirectional turbulent flow of media with flow rate of 12 ml/
min was attained in a two chambered vessel designed in the
laboratory (Figure S6). Luminal surfaces of ePTFE tubes were
coated with endothelial cells and fitted through the common wall
of the chambers after placing valves at one end to establish
unidirectional flow of media (Figure S6). The entire assembly was
placed on a rocker platform inside a 37uCC O 2 incubator and the
speed was adjusted to attain a flow rate of 12 ml/min from each
tube. At the end of the experiment, cells were trypsinized and
counted to assess the adherent population under these conditions.
Blood flow test
The treated and untreated tube pieces of at least 3 cm length
(4 mm internal diameter) were connected to a heart-lung machine
(Stockert III, Sorin Group, Munchen) to pass heparinized blood
over that, with flow rate of 3 litres/min for 72 hrs. They were then
washed briefly in Ca/Mg-containing PBS, fixed with fresh 4%
parafolmaldehyde and blocked with 4% NDS (Normal Donkey
Serum) after washing in 1X PBS 2–3 times. The adherent blood
cells over their luminal surface were visualized by scanning
electron microscopy (SEM) and by confocal microscopy after
immunostaining with mouse anti-CD41 antibody tagged with PE,
rabbit anti-fibronectin and mouse anti-b2actin. The percent area
covered by blood platelets over the luminal surface of untreated or
treated ePTFE tubings was calculated by calculating the percent
area covered by CD41 (platelets marker) using binary image
processing on Zeiss LSM Image Examiner software.
Statistical analysis
The data were analyzed for either t-test (unpaired) or one way
analysis of variance (ANOVA) and Dunnett test using GraphPad
Prism Software (Ver 5.0). (***) for p,0.001, (**) for p,0.01 and (*)
for p,0.05.
Supporting Information
Figure S1 CD133 expression in low density culture condition.
Endothelial cells with low CD133+ population were cultured in
vitro in low cell density culture (see text) and CD133 expression
was analyzed by FACS at 3 and 6 days. Most of the cells at day 0
and day 3 of in vitro culture are CD133- but after day 3 transition
from CD133- to CD133+ occurs and at day 8 endothelial cells
with low CD133+ population change into high CD133+
population.
Found at: doi:10.1371/journal.pone.0007718.s001 (2.15 MB TIF)
Figure S2 Transition of CD133+ to CD133- cells in different
passages during in vitro culture. Endothelial progenitor cells
(EPCs) passage 10 and 15 were taken from low density cultures (A)
Then induced to differentiate into mature endothelial cells (see
methods). Differentiated endothelial cells of at 8 days of
differentiation show typical cobblestone morphology (B). We
observe that during this induction of differentiation of EPCs lose
CD133 expression (C,D). Bar=20 mm.
Found at: doi:10.1371/journal.pone.0007718.s002 (4.25 MB TIF)
Figure S3 Endothelial cells with high CD133+ population has
higher clonogenicity than cells with low CD133+ population.
Endothelial cells with high CD133+ (A) and with low CD133+
population (B) were seeded in 0.8% methylcellulose containing
IMDM media with 30% FBS, 1% BSA, 100 mM mercaptoethanol
and 2 mM L-glutamine in tissue culture treated 30 mm plates for
3 weeks. Colony formation in plates seeded with cells containing
high CD133+ population has been observed (C) while monolayer
of endothelial cells was observed in plates seeded with cells
containing low CD133+ population (D).
Found at: doi:10.1371/journal.pone.0007718.s003 (4.34 MB TIF)
Figure S4 Endothelial cells expanded in low cell density culture
are resistant to hypertrophic morphological changes in higher
passages. Morphologically similar endothelial cells have been
observed when they were differentiated into mature endothelial
(CD133-) by culturing them in high density culture from low
density culture at different passages. (A) shows cell morphology
when passage 1 EPCs were differentiated while (B,C) show cell
morphology of cells at high passage number (10th and 20th
passage), at 8 days after induction of differentiation, respectively.
Bar represents 20 mm.
Found at: doi:10.1371/journal.pone.0007718.s004 (3.45 MB TIF)
Figure S5 Coating of matrices on untreated ePTFE has no effect
on hydrophilicity. Adsorption of protein matrices over untreated
ePTFE rafts was tested by coating them with fibronectin and
OptiMat (74 ng/cm2) overnight at 37uC. Water contact angles
were then measured to observe the change in hydrophobicity of
ePTFE. No significant change in hydrophobicity of ePTFE
compared to that of untreated ePTFE was observed after coating
with these matrices suggesting that pretreatment of ePTFE is
essential for incorporation of hydrophilic residues on to ePTFE.
Found at: doi:10.1371/journal.pone.0007718.s005 (0.77 MB TIF)
Figure S6 Outline of chamber designed for unidirectional flow
stress analysis. A chamber was developed in the laboratory to assess
the ability of endothelialized ePTFE tubings to unidirectional flow
stress. Valves were fixed to either ends of acid-treated and OptiMat
coated endothelialized ePTFE grafts. This assured unidirectional
flow of media through each tube as the entire assembly was placed
on a rocker platform at 37uC in5%CO2 environment. A grey arrow
Endothelialization of ePTFE
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black arrow indicated the flow direction when the valve isopen.This
systemallowsunidirectionalflowofmediathroughePTFEtubingsat
different flow rates under physiological conditions.
Found at: doi:10.1371/journal.pone.0007718.s006 (1.06 MB TIF)
Figure S7 Effect of OptiMat dilution on endothelial cell
adhesion on ePTFE. Different dilutions of OptiMat were tested
to coat acidified glycerol treated ePTFE rafts for endothelial cell
adhesion. Significant adhesion of endothelial cells was observed
even as minimal as 74 ng/cm ˆ 2 coating of OptiMat on ePTFE.
Found at: doi:10.1371/journal.pone.0007718.s007 (0.18 MB TIF)
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